Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironmentsShogo Kumagai, Hiroyoshi Nishikawa, Shohei Koyama et al.|Cancer Cell|2022Cited by 828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Hiroyoshi Nishikawa, Yosuke Togashi et al.|Nature Immunology|2020Cited by 810
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y. Janjigian, Hyun Cheol Chung, Lucjan Wyrwicz et al.|Nature|2021Cited by 687
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y. Janjigian, Sun Young Rha, Akihito Kawazoe et al.|The Lancet|2023Cited by 461
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigmYoshiaki Nakamura, Kohei Shitara, Akihito Kawazoe et al.|Nature Reviews Clinical Oncology|2021Cited by 301